September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more
Taysha Gene Therapies, a preclinical biotech developing gene therapies for very rare CNS disorders, raised $157 million by offering 7.9 million shares at $20, the high end of the range of $18 to $20. The company offered 1.3 million more shares than anticipated....read more
In another busy week for the September IPO market, eight IPOs are scheduled to raise $2.0 billion, led by prescription drug marketplace GoodRx Holdings (GDRX). The largest deal of the week, ...read more
Taysha Gene Therapies, an early stage biotech developing AAV-based gene therapies for CNS disorders, announced terms for its IPO on Thursday. The Dallas, TX-based company plans to raise $125 million by offering 6.6 million shares at a price range of $18 to...read more
US IPO Weekly Recap: Health and tech dominate the calendar in an 11 IPO week
September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more
Preclinical CNS biotech Taysha Gene Therapies prices upsized IPO at $20 high end
Taysha Gene Therapies, a preclinical biotech developing gene therapies for very rare CNS disorders, raised $157 million by offering 7.9 million shares at $20, the high end of the range of $18 to $20. The company offered 1.3 million more shares than anticipated....read more
US IPO Week Ahead: The September IPO calendar stays Good(Rx) and busy in an 8 IPO week
In another busy week for the September IPO market, eight IPOs are scheduled to raise $2.0 billion, led by prescription drug marketplace GoodRx Holdings (GDRX). The largest deal of the week, ...read more
CNS biotech Taysha Gene Therapies sets terms for $125 million IPO
Taysha Gene Therapies, an early stage biotech developing AAV-based gene therapies for CNS disorders, announced terms for its IPO on Thursday. The Dallas, TX-based company plans to raise $125 million by offering 6.6 million shares at a price range of $18 to...read more